Carmot Therapeutics, Inc.
Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group. Carmot Therapeutics is a clinical-stage biotechnology company that is focused on advancing life-changing therapeutics for people with obesity and diabetes. We are utilizing Chemotype Evolution, a pioneering drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics that have the potential to produce significant weight loss and improved glycemic control. We have three clinical candidates: CT-388, CT-868 and CT-996.
NEWS
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.
Money on the Move: A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
Under the deal, Carmot will use its lead-identification technology to identify and advance novel drug leads for Parkinson’s disease and other disease areas.
JOBS
IN THE PRESS